{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:12Z","timestamp":1793382972332,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","award":["N371A"],"award-info":[{"award-number":["N371A"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jgar.2025.10.002","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:37:19Z","timestamp":1760222239000},"page":"215-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["96-week real-world effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV-infected adults with pre-existing NRTI resistance: A retrospective cohort study"],"prefix":"10.1016","volume":"45","author":[{"given":"Laura","family":"Mezzogori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Muccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Schiavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-6358","authenticated-orcid":false,"given":"Lucia","family":"Taramasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Giacomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Stefanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Randazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Maggiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-6281","authenticated-orcid":false,"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-5089","authenticated-orcid":false,"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.10.002_bib0001","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1097\/QAD.0000000000003311","article-title":"Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment experience patients","volume":"36","author":"Mic\u00e1n","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2025.10.002_bib0002","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.10.002_bib0003","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jgar.2022.06.027","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice","volume":"30","author":"Armenia","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.10.002_bib0004","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/QAI.0000000000002454","article-title":"Switching to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (B\/F\/TAF) From Dolutegravir (DTG)+F\/TAF or DTG+F\/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance","volume":"85","author":"Acosta","year":"2020","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2025.10.002_bib0005","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/QAD.0000000000003244","article-title":"High efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in people with suppressed HIV and preexisting M184V\/I","volume":"36","author":"Sax","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2025.10.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027330","article-title":"Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with HIV","volume":"100","author":"Rolle","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jgar.2025.10.002_bib0007","doi-asserted-by":"crossref","first-page":"ofaf087","DOI":"10.1093\/ofid\/ofaf087","article-title":"Three-Year Effectiveness of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide as a Switch Strategy in the Real World","volume":"12","author":"De Gea-Grela","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.002_bib0008","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.jgar.2025.10.002_bib0009","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e328356886d","article-title":"High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen","volume":"26","author":"Sunpath","year":"2012","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.jgar.2025.10.002_bib0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/aid.2017.0295","article-title":"Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States","volume":"34","author":"Ross","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jgar.2025.10.002_bib0011","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/aid.2017.0064","article-title":"From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital Platform Improved Doctors\u2019 Work and Patients\u2019 Care","volume":"34","author":"Giannini","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jgar.2025.10.002_bib0012","unstructured":"Antiviral Response Cohort Analysis (ARCA) n.d."},{"key":"10.1016\/j.jgar.2025.10.002_bib0013","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.10.002_bib0014","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/hiv.13376","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in patients with genotypic NRTI resistance","volume":"24","author":"Shafran","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2025.10.002_bib0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QAI.0000000000002731","article-title":"Switching to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study","volume":"88","author":"Hagins","year":"2021","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2025.10.002_bib0016","article-title":"Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV\u202f: Real-world insights from BICSTaR cohorts","author":"Esser","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2025.10.002_bib0017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2022.11.012","article-title":"Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N\/R mutation","volume":"126","author":"Tsai","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2025.10.002_bib0018","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jgar.2025.10.002_bib0019","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/jac\/dkv083","article-title":"Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database","volume":"70","author":"Raffi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.10.002_bib0020","unstructured":"EACS Guidelines version 12.1, November 2024 n.d."},{"key":"10.1016\/j.jgar.2025.10.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"eClinicalMedicine"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:04:51Z","timestamp":1780783491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"alternative-id":["S2213716525002206"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.10.002","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"96-week real-world effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV-infected adults with pre-existing NRTI resistance: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}